期刊论文详细信息
FEBS Letters
The hepoxilin analog PBT‐3 inhibits heparin‐activated platelet aggregation evoked by ADP
Pace-Asciak, C.R.1  Hinek, Alexander1  Reynaud, D.1 
[1] Programme in Integrative Biology, Research Institute, Hospital for Sick Children, Toronto, ON, Canada M5G 1X8
关键词: Hepoxilin;    PBT-3;    Heparin;    Aggregation;    ADP;    PBT;    hepoxilin cyclopropane analogs;    PBT-3;    10(S)-hydroxy-11;    12-cyclopropyl-eicosa-5Z;    8Z;    14Z-trienoic acid methyl ester;    I-BOP;    5-heptenoic acid;    7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-;    [15-[1α;    2α(Z);    3β(1E;    3S*);    4α]];    U46619;    5-heptenoic acid;    7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo-[2.2.1]-hept-5yl]-[1R-[1α;    4α;    5β(Z);    6α(1E;    3S*)]-9;    11-dideoxy-9α;    11α-methanoepoxy prostaglandin F2α;    SQ 29;    548;    [1S-[1a;    2a(Z);    3a;    4a]]-7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid;   
DOI  :  10.1016/S0014-5793(02)02434-1
学科分类:生物化学/生物物理
来源: John Wiley & Sons Ltd.
PDF
【 摘 要 】

We have previously shown that PBT-3, a stable synthetic analog of hepoxilins, inhibits the aggregation of human platelets in vitro evoked by collagen through inhibition of thromboxane A2 formation and action on the TP receptor. We now show that PBT-3 is capable of potently inhibiting the second phase of aggregation evoked by ADP in both washed human platelets and platelet-rich plasma (PRP), a phase associated with thromboxane formation. Aspirin blocks this second phase as well; so does the thromboxane receptor antagonist SQ 29,548. When ADP-evoked aggregation in PRP is activated by heparin through an enhancement of thromboxane formation, PBT-3, aspirin as well as SQ 29,548 block this activation through different mechanisms. These data confirm the inhibitory action of PBT-3 on aggregation of human platelets through inhibition of both thromboxane formation and blockade of thromboxane receptor action and suggest that this family of compounds may be useful in the treatment of thrombotic disorders in combination with heparin.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912020311611ZK.pdf 86KB PDF download
  文献评价指标  
  下载次数:24次 浏览次数:21次